CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
CNMDLARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair. “Today’s announcement reflects a positive step in our strategic portfolio review and o
CONMED Corporation Adds Kim Kelderman to its Board of Directors
CNMD(NYSE:CNMD) LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Kim Kelderman will be joining its Board of Directors effective September 8, 2025. “My fellow directors and I are delighted to welcome Kim to the board,” said LaVerne Council, Chair of CONMED’s Board of Directors. “Kim brings extensive global leadership experience across life sciences businesses, with a strong track record in innovation and strategy. Kim’s skills and insights will be valuable additions to the boar
CONMED Corporation Announces Quarterly Cash Dividend
CNMDLARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties, inc
Demystifying Conmed: Insights From 5 Analyst Reviews
CNMDNeedham Downgrades Conmed to Hold, Maintains Price Target to $61
CNMDCONMED Appoints Laverne Council To Succeed Martha Goldberg Aronson As Independent Chair Of The Board Of Directors, Effective May 21, 2025
CNMDJP Morgan Maintains Neutral on Conmed, Lowers Price Target to $58
CNMDWells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $57
CNMDBreaking Down Conmed: 6 Analysts Share Their Views
CNMDNeedham Maintains Buy on Conmed, Lowers Price Target to $61
CNMDCORRECTION: Conmed Q1 Adj. EPS $0.95 Beats $0.81 Estimate, Sales $321.30M Beat $313.37M Estimate
CNMDConmed Raises FY2025 Adj EPS Guidance from $4.25-$4.40 to $4.45-$4.60 vs $4.34 Est; Raises FY2025 Sales Guidance from $1.34B-$1.37B to $1.35B-$1.38B vs $1.36B Est
CNMDConmed Q1 Adj. EPS $0.85 Beats $0.81 Estimate, Sales $321.30M Beat $313.37M Estimate
CNMDStifel Downgrades Conmed to Hold, Lowers Price Target to $55
CNMDNeedham Reiterates Buy on Conmed, Maintains $97 Price Target
CNMDCONMED Reports Purchase Of In2Bones Global For $145M In Cash At Closing, Up To Added $110M In Growth-Based Earnout Payments Over 4-Year Period
CNMDUPDATE: CONMED Raises FY22 Sales Guidance From $1.075B-$1.125B To $1.105B-$1.15B vs $1.09B Est. Adj. EPS From $3.60-$3.85 To $3.50-$3.65 vs $3.69 Est.
CNMDConmed Q1 EPS $0.70 Beats $0.62 Estimate, Sales $242.33M Beat $235.77M Estimate; Raises Guidance
CNMDRecap: Conmed Q1 Earnings
CNMDConmed (NYSE:CNMD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Conmed beat estimated earnings by 12.9%, reporting an EPS of $0.7 versus an estimate of $0.62.
